You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 29, 2024

ASPRUZYO SPRINKLE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Aspruzyo Sprinkle, and what generic alternatives are available?

Aspruzyo Sprinkle is a drug marketed by Spil and is included in one NDA. There are two patents protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in ASPRUZYO SPRINKLE is ranolazine. There are twenty-three drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the ranolazine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Aspruzyo Sprinkle

A generic version of ASPRUZYO SPRINKLE was approved as ranolazine by CHARTWELL RX on July 29th, 2013.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ASPRUZYO SPRINKLE?
  • What are the global sales for ASPRUZYO SPRINKLE?
  • What is Average Wholesale Price for ASPRUZYO SPRINKLE?
Summary for ASPRUZYO SPRINKLE
International Patents:1
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Drug Prices: Drug price information for ASPRUZYO SPRINKLE
What excipients (inactive ingredients) are in ASPRUZYO SPRINKLE?ASPRUZYO SPRINKLE excipients list
DailyMed Link:ASPRUZYO SPRINKLE at DailyMed
Drug patent expirations by year for ASPRUZYO SPRINKLE
Drug Prices for ASPRUZYO SPRINKLE

See drug prices for ASPRUZYO SPRINKLE

US Patents and Regulatory Information for ASPRUZYO SPRINKLE

ASPRUZYO SPRINKLE is protected by two US patents.

Patents protecting ASPRUZYO SPRINKLE

Extended release multiparticulates of ranolazine
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Extended release multiparticulates of ranolazine
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Spil ASPRUZYO SPRINKLE ranolazine GRANULES, EXTENDED RELEASE;ORAL 216018-002 Feb 28, 2022 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Spil ASPRUZYO SPRINKLE ranolazine GRANULES, EXTENDED RELEASE;ORAL 216018-002 Feb 28, 2022 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Spil ASPRUZYO SPRINKLE ranolazine GRANULES, EXTENDED RELEASE;ORAL 216018-001 Feb 28, 2022 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for ASPRUZYO SPRINKLE

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Menarini International Operations Luxembourg S.A. (MIOL) Ranexa (previously Latixa) ranolazine EMEA/H/C/000805
Ranexa is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti-anginal therapies (such as beta-blockers and / or calcium antagonists).,
Authorised no no no 2008-07-08
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for ASPRUZYO SPRINKLE

See the table below for patents covering ASPRUZYO SPRINKLE around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 3409273 FORMULATIONS MULTIPARTICULAIRES À LIBÉRATION PROLONGÉE DE RANOLAZINE (EXTENDED RELEASE MULTIPARTICULATES OF RANOLAZINE) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ASPRUZYO SPRINKLE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1109558 SPC/GB08/058 United Kingdom ⤷  Sign Up PRODUCT NAME: RANOLAZINE OR A SALT OR SOLVATE THEREOF; REGISTERED: UK EU/1/08/462/001 20080714; UK EU/1/08/462/002 20080714; UK EU/1/08/462/003 20080714; UK EU/1/08/462/004 20080714; UK EU/1/08/462/005 20080714; UK EU/1/08/462/006 20080714
1109558 2008/034 Ireland ⤷  Sign Up PRODUCT NAME: RANOLAZINE OR A SALT THEREOF; REGISTRATION NO/DATE: EU/1/08/462/001 20080709
1109558 09C0001 France ⤷  Sign Up PRODUCT NAME: RANOLAZINE; REGISTRATION NO/DATE: EU/1/08/462/001-006 20080714
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.